Related Experiment Video

Updated: Jun 6, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant

Mohamed H Ahmed1, Atif A Khalil

  • 1Division of Acute Medicine, The James Cook University Hospital, Marton Road, Middlesbrough, United Kingdom. elziber@yahoo.com

Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia
|November 10, 2010
PubMed

Insights

Adding ezetimibe to statin therapy is safe and effective for managing dyslipidemia in patients with chronic kidney disease (CKD) and kidney transplant recipients. Further research is needed to confirm cardiovascular risk reduction in CKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) accelerates atherosclerosis, a major cause of death in kidney transplant recipients.
  • Cardiovascular disease (CVD) is a leading cause of mortality in CKD and transplant populations.
  • Lipid-lowering medications, particularly statins, show potential for CVD prevention in these groups.

Purpose of the Study:

  • To evaluate the efficacy and safety of adding ezetimibe to statin therapy for dyslipidemia in CKD and kidney transplant patients.
  • To assess the effectiveness of combined ezetimibe and simvastatin in managing refractory dyslipidemia.
  • To investigate the role of lipid-lowering agents in reducing cardiovascular events in renal disease.

Main Methods:

  • The Study of Heart and Renal Protection (SHARP) trial involves 9,000 CKD patients.
  • Participants receive either ezetimibe 10 mg plus simvastatin 20 mg daily or a placebo.
  • The study evaluates the impact of lowering low-density lipoprotein cholesterol (LDL-C) on cardiovascular outcomes.

Main Results:

  • Previous studies (UK-HARP-II) demonstrated the safety and effectiveness of ezetimibe/simvastatin combination in CKD.
  • The combination therapy was also found to be effective and safe in kidney transplant recipients.
  • Current evidence supports ezetimibe addition to statins for dyslipidemia in CKD and transplant patients.

Conclusions:

  • Ezetimibe in combination with statin therapy is a safe and effective treatment for dyslipidemia in CKD and kidney transplant patients.
  • Further clinical trials are necessary to determine if ezetimibe reduces cardiovascular risk in CKD patients.
  • The SHARP trial will provide crucial data on the cardiovascular benefits of LDL-C lowering in CKD.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...